Worth reading
48Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-14.9
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 October 2025 to 30 September 2026ConsolidatedJapanese GAAPNet Sales62,651Millions of yenYear on year -3.2%Progress 97.4%
Operating profit9,424Millions of yenYear on year -14.9%Progress 90.6%
Ordinary income9,896Millions of yenYear on year -16.0%Progress 91.6%
Net income attributable to owners of the parent8,216Millions of yenYear on year +2.3%Progress 99.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥240.56
Operating MarginCurrent fiscal year 15 % / Previous period 17.1 %
Financial position at period-end
Total assets75,448Millions of yen
of which net assets 54,630 Millions of yenEquity ratio 71.8%vs. prior year-end +1.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+4,676
Investment+2,072
Financials-8,178
Net change-1,430
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period25,458 Millions of yen
Segment revenueCosmetics Business 49,055 Millions of yen (YoY -2.9%), Pharmaceuticals and food business 11,049 Millions of yen (YoY -4.2%), Other Businesses 2,546 Millions of yen (YoY -4.4%)
Segment profitCosmetics Business 11,066 Millions of yen (YoY -10.0%), Pharmaceuticals and food business 666 Millions of yen (YoY -32.0%), Other Businesses 286 Millions of yen (YoY -4.9%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales64,300 Millions of yen (YoY +2.6%)
Operating profit10,400 Millions of yen (YoY +10.4%)
Ordinary income10,800 Millions of yen (YoY +9.1%)
Net income8,300 Millions of yen (YoY +1.0%)
Annual Dividend Forecast232 Yen → 232 Yen（0.0%）
Payout ratioFiscal year ended September 2025 97.8 % / Fiscal year ending September 2026 96.4 % / Forecast for the fiscal year ending September 2027 95.5 %
Shareholder Return PolicyPolicy of continuing stable dividend payments. Numerical target: Not disclosed.
Factors Behind Changes in Business Performance
Although the economy showed signs of a gradual recovery, it remained uncertain due in part to the impact of the situation in the Middle East. For the next fiscal year, the company expects risks including downward pressure on personal consumption from rising prices.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationMaterial changes No / New Not disclosed / Excluded Not disclosed / Company name Not disclosed
Material subsequent eventsNot applicable.
Impairment loss¥120 million (Pharmaceuticals and Food segment)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of fixed assets 932 Millions of yen, Gain on sales of investment securities 1,451 Millions of yen / Extraordinary loss Loss on disposal and sale of non-current assets 3 Millions of yen, Impairment loss 120 Millions of yen, Loss on cancellation of insurance policies 164 Millions of yen
Depreciation and amortization1,025 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End34,156,623 shares
Treasury Shares at Period-End417 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025 to 30 September 2026 |
| Net Sales | 62,651 Millions of yen (YoY -3.2%) |
| Operating profit | 9,424 Millions of yen (YoY -14.9%) |
| Ordinary income | 9,896 Millions of yen (YoY -16.0%) |
| Profit attributable to owners of the parent | 8,216 Millions of yen (YoY +2.3%) |
| Net income per share | ¥240.56 |
| Operating Margin | Current fiscal year 15 % / Previous period 17.1 % |
| Equity ratio | End of the current fiscal period 71.8 / End of previous period 70.3 |
| Total assets | 75,448 Millions of yen |
| Net assets | 54,630 Millions of yen |
| Cash flows from operating activities | 4,676 Millions of yen |
| Cash flows from investing activities | 2,072 Millions of yen |
| Cash flows from financing activities | -8,178 Millions of yen |
| Cash and cash equivalents at end of period | 25,458 Millions of yen |
| Full-year earnings forecast | Net Sales 64,300 Millions of yen (YoY +2.6%) / Operating profit 10,400 Millions of yen (YoY +10.4%) / Ordinary income 10,800 Millions of yen (YoY +9.1%) / Net income 8,300 Millions of yen (YoY +1.0%) |
| Annual Dividend Forecast | 232 Yen → 232 Yen（0.0%） |
| Payout ratio | Fiscal year ended September 2025 97.8 % / Fiscal year ending September 2026 96.4 % / Forecast for the fiscal year ending September 2027 95.5 % |
| Shareholder Return Policy | Policy of continuing stable dividend payments. Numerical target: Not disclosed. |
| Segment revenue | Cosmetics Business 49,055 Millions of yen (YoY -2.9%), Pharmaceuticals and food business 11,049 Millions of yen (YoY -4.2%), Other Businesses 2,546 Millions of yen (YoY -4.4%) |
| Segment profit | Cosmetics Business 11,066 Millions of yen (YoY -10.0%), Pharmaceuticals and food business 666 Millions of yen (YoY -32.0%), Other Businesses 286 Millions of yen (YoY -4.9%) |
| Depreciation and amortization | 1,025 Millions of yen |
| Impairment loss | ¥120 million (Pharmaceuticals and Food segment) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets 932 Millions of yen, Gain on sales of investment securities 1,451 Millions of yen / Extraordinary loss Loss on disposal and sale of non-current assets 3 Millions of yen, Impairment loss 120 Millions of yen, Loss on cancellation of insurance policies 164 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Material changes No / New Not disclosed / Excluded Not disclosed / Company name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 34,156,623 shares |
| Treasury Shares at Period-End | 417 shares |
| Factors Behind Changes in Business Performance | Although the economy showed signs of a gradual recovery, it remained uncertain due in part to the impact of the situation in the Middle East. For the next fiscal year, the company expects risks including downward pressure on personal consumption from rising prices. |
Items this document does not state (3)
Revision to Earnings ForecastRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the economy showed signs of a gradual recovery, it remained uncertain due in part to the impact of the situation in the Middle East. For the next fiscal year, the company cites risks including downward pressure on personal consumption from rising prices.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.